Zofran (ondansetron) MDL Arguments Heard October 1, 2015
October 1st was a significant day in the Zofran (ondansetron) litigation, as the Judicial Panel on Multidistrict Litigation met to consider the arguments for consolidating several lawsuits against the anti-nausea drug’s manufacturer, GlaxoSmithKline (“GSK”). The ruling will be the first big step in the litigation, as plaintiffs are vying to have their cases centralized before …. Read More